Vir Biotechnology is an immunology company that develops products to treat and prevent infectious diseases and other serious conditions.
Vir Biotechnology has raised $25.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2026.
Vir Biotechnology's investors include ARCH Venture Partners, S32, 8VC, Alta Partners, Gilead Sciences.
Vir Biotechnology is headquartered in San Francisco, United States.
Vir Biotechnology is an immunology company that develops products to treat and prevent infectious diseases and other serious conditions.
Vir Biotechnology is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vir Biotechnology — Funding & Investors." VCBacked, October 14, 2026, https://www.vcbacked.co/company/vir-biotechnology. Accessed November 12, 2026.
VCBacked. (2026). Vir Biotechnology — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/vir-biotechnology
{{cite web |title=Vir Biotechnology — Funding & Investors |url=https://www.vcbacked.co/company/vir-biotechnology |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Vir Biotechnology? Request a listing update